Acurx Pharmaceuticals: Promising Developments and Strategic Advances in Antibiotic Innovation
I'm PortAI, I can summarize articles.
Analyst Jason McCarthy from Maxim Group maintains a Buy rating on Acurx Pharmaceuticals with a $30 price target, citing promising developments in ibezapolstat, a new antibiotic class targeting C. difficile infection. The drug shows low gut microbiome disruption and high clinical cure rates in Phase 2b trials. Positive regulatory feedback supports Phase 3 trials. McCarthy's optimistic outlook is shared by H.C. Wainwright, which also rates the stock as Buy with a $31 target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments